ARTICLES

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
Pharmacological Narcolepsy Research & Studies

Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

Alkermes plc today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly referred to as ALKS 2680, is the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as […]

Pediatric Health Behavioral & Mental Health Research & Studies

Sleep To Live Well Foundation Launches With Groundbreaking Sleep Wellness Report

The Sleep To Live Well Foundation issues an urgent warning in its groundbreaking 2025 State of Sleep Wellness Report, titled “THE SILENT EPIDEMIC: How Lack of Sleep Endangers Over Half of All Americans and Threatens Everyone.” The report unveils the Foundation’s initiatives to address this insufficient sleep crisis with Sleep Wellness—a holistic approach to […]

SleepWorld Magazine

Are the Tariffs Keeping You Up at Night?

Sleep labs and suppliers across the U.S. are bracing for the economic ripple effects of sweeping new tariffs on imported goods. Consider, for example, a typical sleep diagnostic test. It might consist of a small machine, a box with plastic casing that houses electronics. Many of its components—the plastic or […]

Pharmacological Narcolepsy

Avadel’s LUMRYZ Approval Upheld in Court

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) affirmed a prior decision of the U.S. District Court for the District of Columbia (the “District […]